KAS
MDGL icon

Kestra Advisory Services’s Madrigal Pharmaceuticals MDGL Stock Holding History

Kestra Advisory Services’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$725K Sell
1,350
-12
-0.9% -$6.15K ﹤0.01% 2049
2026
Q1 		$713K Sell
1,362
-218
-14% -$104K ﹤0.01% 1964
2025
Q4 		$920K Buy
1,580
+13
+0.8% +$6.64K ﹤0.01% 1714
2025
Q3 		$719K Sell
1,567
-98
-6% -$36.6K ﹤0.01% 1821
2025
Q2 		$504K Sell
1,665
-41
-2% -$12.2K ﹤0.01% 1958
2025
Q1 		$565K Buy
1,706
+1
+0.1% +$329 ﹤0.01% 1740
2024
Q4 		$526K Sell
1,705
-909
-35% -$256K ﹤0.01% 1842
2024
Q3 		$555K Buy
2,614
+145
+6% +$37.1K ﹤0.01% 1707
2024
Q2 		$692K Sell
2,469
-115
-4% -$27.4K ﹤0.01% 1559
2024
Q1 		$690K Sell
2,584
-1,020
-28% -$240K ﹤0.01% 1463
2023
Q4 		$834K Sell
3,604
-2
-0.1% -$350 0.01% 1220
2023
Q3 		$527K Buy
3,606
+25
+0.7% +$4.71K 0.01% 1344
2023
Q2 		$827K Buy
3,581
+1,021
+40% +$277K 0.01% 1069
2023
Q1 		$620K Buy
2,560
+104
+4% +$28.3K 0.01% 1169
2022
Q4 		$713K Buy
+2,456
New +$240K 0.01% 1212

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kestra Advisory Services's MDGL Position: Q2 2026 in Review

Kestra Advisory Services reduced its Madrigal Pharmaceuticals (MDGL) stake by 0.88% in Q2 2026, selling an estimated $6.15K and leaving 1,350 shares worth $725K. The position accounts for ﹤0.01% of the portfolio, ranked #2049.

Kestra Advisory Services first reported a position in MDGL in Q4 2022 and has held it in 15 quarters since. The position peaked at $920K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Kestra Advisory Services held 1,350 shares of Madrigal Pharmaceuticals worth $725K as of Q2 2026.
  • Kestra Advisory Services sold 12 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $6.15K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #2049 holding.
  • Kestra Advisory Services first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Kestra Advisory Services's Madrigal Pharmaceuticals position peaked at $920K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.